written on 25.06.2014
Tags:
,

GSK expects to meet flu vaccine demand but even short interruptions can be costly

TAGS: ,

GlaxoSmithKline, responding to an FDA warning letter sent to the plant that produces its FluLaval and other influenza vaccines for the U.S. and Canada, said it expects to be on track to produce more than 30 million doses for the upcoming flu season. But the experience of other drugmakers suggests that even a small hiccup in producing a vaccine for a crucial cycle can be significant to a drugmaker's top and bottom lines.

Latest Report